Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma

Area of Science:

• Oncology
• Pulmonology
• Genetics

Background:

• Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine lung cancer (HGNEC).
• It accounts for 3% of primary lung cancers, presenting with aggressive invasion and poor prognosis.
• Current diagnosis and treatment often mimic small cell lung cancer (SCLC), lacking tailored approaches.

Purpose of the Study:

• To review current diagnostic criteria for LCNEC.
• To elucidate the molecular characteristics driving LCNEC.
• To summarize emerging and frontier treatment strategies for LCNEC.

Main Methods:

• Comprehensive literature review of existing research on LCNEC.
• Analysis of recent genetic studies and clinical trial data.
• Synthesis of findings to identify trends and future directions.

Main Results:

• LCNEC diagnosis remains challenging due to heterogeneity.
• Emerging genetic analyses are revealing distinct molecular subtypes.
• Clinical trials are beginning to inform more precise therapeutic strategies.

Conclusions:

• LCNEC requires distinct diagnostic and therapeutic approaches beyond SCLC protocols.
• Understanding LCNEC molecular landscape is crucial for targeted therapies.
• Future research should focus on precision medicine for improved LCNEC management.